First, statin treatment can attenuate NAFLD via a reduction in lipid accumulation in the liver [19,27,28], while statin treatment can upregulate PCSK9 expression in the liver and PCSK9 levels in the blood [13,16,29,30]. This evidence concerns the gene PCSK9 and metabolic dysfunction-associated steatotic liver disease.